5 Key Takeaways
-
1
Semaglutide, a GLP-1RA, may be linked to ischaemic optic neuropathy (ION), raising concerns for clinicians and ophthalmologists.
-
2
An analysis of over 30 million FDA adverse event reports identified semaglutide as the only GLP-1RA significantly associated with ION.
-
3
Wegovy, the higher-dose semaglutide for obesity, showed the strongest association with ION, nearly five times higher than Ozempic.
-
4
Sex-specific differences were noted, with men on Wegovy having higher ION reporting odds, while Ozempic cases were more common in women.
-
5
No ION signal was found with tirzepatide or comparator drugs, indicating a need for further research on semaglutide's ocular effects.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
